Skip to content
Disclosery

SR One Capital Management, LP

Follow

13F filer, CIK 1910264, Redwood City, CA

SR One Capital Management, LP reported $691,412,158 across 12 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12. Its ten largest share positions make up 98.44% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-25-277769

Period
2025-09-30
Reported value
$691M
Holdings
12
Top 10 weight
98.44%
New
0
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CRSPadded+989,812$64.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MLYSreduced-1,014,000-$38.5M
KALAexited-598,940-$2.85M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001193125-25-277769, largest first. % of portfolio is the value over $691,412,158, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,346,630 shares; 2024Q4: 2,346,630 shares; 2025Q1: 2,346,630 shares; 2025Q2: 2,346,630 shares; 2025Q3: 2,346,630 shares 2,346,630$193M27.86%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,048,951 shares; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares; 2025Q2: 1,048,951 shares; 2025Q3: 2,038,763 shares 2,038,763$132M19.11%+989,812Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,911,539 shares; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares; 2025Q2: 4,911,539 shares; 2025Q3: 4,911,539 shares 4,911,539$109M15.77%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,016,822 shares; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares; 2025Q2: 3,127,933 shares; 2025Q3: 2,113,933 shares 2,113,933$80.2M11.59%-1,014,000Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,514,929 shares; 2025Q3: 4,514,929 shares 4,514,929$54.2M7.84%0Timeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,526,476 shares; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares; 2025Q2: 6,526,476 shares; 2025Q3: 6,526,476 shares 6,526,476$49.1M7.11%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,012,903 shares; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares; 2025Q2: 4,012,903 shares; 2025Q3: 4,012,903 shares 4,012,903$40.3M5.83%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 375,330 shares; 2024Q4: 430,330 shares; 2025Q1: 430,330 shares; 2025Q2: 430,330 shares; 2025Q3: 430,330 shares 430,330$8.28M1.2%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,959,896 shares; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares; 2025Q2: 1,959,896 shares; 2025Q3: 1,959,896 shares 1,959,896$7.82M1.13%0Timeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,333,333 shares; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares; 2025Q2: 3,333,333 shares; 2025Q3: 3,333,333 shares 3,333,333$6.9M1%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 322,500 shares; 2025Q2: 322,500 shares; 2025Q3: 322,500 shares 322,500$5.67M0.82%0Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 747,750 shares; 2024Q4: 747,750 shares; 2025Q1: 747,750 shares; 2025Q2: 747,750 shares; 2025Q3: 747,750 shares 747,750$5.11M0.74%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
KALAKALA BIO INC598,940$2.85Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-25-277769 base2025-11-12acceptance time not in the bulk data set